Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.56%
0%
-22.56%
6 Months
-22.94%
0%
-22.94%
1 Year
-14.19%
0%
-14.19%
2 Years
5.83%
0%
5.83%
3 Years
91.27%
0%
91.27%
4 Years
85.46%
0%
85.46%
5 Years
120.49%
0%
120.49%
Ypsomed Holding AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.36%
EBIT Growth (5y)
95.33%
EBIT to Interest (avg)
12.32
Debt to EBITDA (avg)
1.99
Net Debt to Equity (avg)
0.49
Sales to Capital Employed (avg)
0.70
Tax Ratio
16.12%
Dividend Payout Ratio
34.31%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.53%
ROE (avg)
8.42%
Valuation key factors
Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
6.18
EV to EBIT
34.05
EV to EBITDA
21.27
EV to Capital Employed
4.48
EV to Sales
6.05
PEG Ratio
4.12
Dividend Yield
0.72%
ROCE (Latest)
13.16%
ROE (Latest)
12.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Mar'23
Mar'23
Mar'22
Change(%)
Net Sales
497.50
464.80
7.04%
Operating Profit (PBDIT) excl Other Income
115.90
92.50
25.30%
Interest
2.30
2.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
51.30
23.10
122.08%
Operating Profit Margin (Excl OI)
75.00%
52.50%
2.25%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2023 is 7.04% vs 15.14% in Mar 2022
Consolidated Net Profit
YoY Growth in year ended Mar 2023 is 122.08% vs 298.28% in Mar 2022
About Ypsomed Holding AG 
Ypsomed Holding AG
Pharmaceuticals & Biotechnology
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.






